Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite

Background and Purpose Nitrite (NO2−) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO2− in healthy volunteers and patients with stable congestive heart failure (CHF). Exp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of pharmacology 2013-06, Vol.169 (3), p.659-670
Hauptverfasser: Maher, Abdul R, Arif, Sayqa, Madhani, Melanie, Abozguia, Khalid, Ahmed, Ibrar, Fernandez, Bernadette O, Feelisch, Martin, O'Sullivan, AG, Christopoulos, Arthur, Sverdlov, Aaron L, Ngo, Doan, Dautov, Rustem, James, Philip E, Horowitz, John D, Frenneaux, Michael P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 670
container_issue 3
container_start_page 659
container_title British journal of pharmacology
container_volume 169
creator Maher, Abdul R
Arif, Sayqa
Madhani, Melanie
Abozguia, Khalid
Ahmed, Ibrar
Fernandez, Bernadette O
Feelisch, Martin
O'Sullivan, AG
Christopoulos, Arthur
Sverdlov, Aaron L
Ngo, Doan
Dautov, Rustem
James, Philip E
Horowitz, John D
Frenneaux, Michael P
description Background and Purpose Nitrite (NO2−) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO2− in healthy volunteers and patients with stable congestive heart failure (CHF). Experimental Approach The acute haemodynamic effects of brachial artery infusion of NO2− (0.31 to 7.8 μmol·min−1) was assessed in normal subjects (n = 20) and CHF patients (n = 21). Key Results NO2− infusion was well tolerated in all subjects. Forearm blood flow (FBF) increased markedly in CHF patients at NO2− infusion rates which induced no changes in normal subjects (anova: F = 5.5; P = 0.02). Unstressed venous volume (UVV) increased even with the lowest NO2− infusion rate in all subjects (indicating venodilation), with CHF patients being relatively hyporesponsive compared with normal subjects (anova: F = 6.2; P = 0.01). There were no differences in venous blood pH or oxygen concentration between groups or during NO2− infusion. Venous plasma NO2− concentrations were lower in CHF patients at baseline, and rose substantially less with NO2− infusion, without incremental oxidative generation of nitrate, consistent with accelerated clearance in these patients. Plasma protein‐bound NO concentrations were lower in CHF patients than normal subjects at baseline. This difference was attenuated during NO2− infusion. Prolonged NO2− exposure in vivo did not induce oxidative stress, nor did it induce tolerance in vitro. Conclusions and Implications The findings of arterial hyper‐responsiveness to infused NO2− in CHF patients, with evidence of accelerated transvascular NO2− clearance (presumably with concomitant NO release) suggests that NO2− effects may be accentuated in such patients. These findings provide a stimulus for the clinical exploration of NO2− as a therapeutic modality in CHF.
doi_str_mv 10.1111/bph.12152
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3682712</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3316012971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4762-15ec056cc388b3837003ca71b5d15c4d8c5cbf01ed2cb294a03905170d5b403b3</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhS1ERYfCghdAltjAIq1_4rFngwQV_ZEqtQtYW87NzcQlsYOdDOrb4zKlokh448X99PlcH0LecHbMyzlppv6YC67EM7LitV5XShr-nKwYY7ri3JhD8jLnW8bKUKsX5FDIWgujNyuyvRwnBzONHYU-xeCBQgxbzLPfIe3RpZl2zg9LQhoDnXqXRgfxuw84e8jUhZbuXI5jnGOi2HUIc763-dAtGVsa_Jz8jK_IQeeGjK8f7iPy7ezL19OL6ur6_PL001UFJbeouEJgag0gjWmkkZoxCU7zRrVcQd0aUNB0jGMroBGb2jG5YYpr1qqmZrKRR-Tj3jstzYgtYJiTG-yU_OjSnY3O26eT4Hu7jTsr10ZoLorg_YMgxR9L-Qc7-gw4DC5gXLLlJVR5WEtW0Hf_oLdxSaGsZ0sXZi3qut4U6sOeghRzTtg9huHM3tdnS332d32Ffft3-kfyT18FONkDP_2Ad_832c83F3vlL8EqpbU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1528624449</pqid></control><display><type>article</type><title>Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Maher, Abdul R ; Arif, Sayqa ; Madhani, Melanie ; Abozguia, Khalid ; Ahmed, Ibrar ; Fernandez, Bernadette O ; Feelisch, Martin ; O'Sullivan, AG ; Christopoulos, Arthur ; Sverdlov, Aaron L ; Ngo, Doan ; Dautov, Rustem ; James, Philip E ; Horowitz, John D ; Frenneaux, Michael P</creator><creatorcontrib>Maher, Abdul R ; Arif, Sayqa ; Madhani, Melanie ; Abozguia, Khalid ; Ahmed, Ibrar ; Fernandez, Bernadette O ; Feelisch, Martin ; O'Sullivan, AG ; Christopoulos, Arthur ; Sverdlov, Aaron L ; Ngo, Doan ; Dautov, Rustem ; James, Philip E ; Horowitz, John D ; Frenneaux, Michael P</creatorcontrib><description>Background and Purpose Nitrite (NO2−) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO2− in healthy volunteers and patients with stable congestive heart failure (CHF). Experimental Approach The acute haemodynamic effects of brachial artery infusion of NO2− (0.31 to 7.8 μmol·min−1) was assessed in normal subjects (n = 20) and CHF patients (n = 21). Key Results NO2− infusion was well tolerated in all subjects. Forearm blood flow (FBF) increased markedly in CHF patients at NO2− infusion rates which induced no changes in normal subjects (anova: F = 5.5; P = 0.02). Unstressed venous volume (UVV) increased even with the lowest NO2− infusion rate in all subjects (indicating venodilation), with CHF patients being relatively hyporesponsive compared with normal subjects (anova: F = 6.2; P = 0.01). There were no differences in venous blood pH or oxygen concentration between groups or during NO2− infusion. Venous plasma NO2− concentrations were lower in CHF patients at baseline, and rose substantially less with NO2− infusion, without incremental oxidative generation of nitrate, consistent with accelerated clearance in these patients. Plasma protein‐bound NO concentrations were lower in CHF patients than normal subjects at baseline. This difference was attenuated during NO2− infusion. Prolonged NO2− exposure in vivo did not induce oxidative stress, nor did it induce tolerance in vitro. Conclusions and Implications The findings of arterial hyper‐responsiveness to infused NO2− in CHF patients, with evidence of accelerated transvascular NO2− clearance (presumably with concomitant NO release) suggests that NO2− effects may be accentuated in such patients. These findings provide a stimulus for the clinical exploration of NO2− as a therapeutic modality in CHF.</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.12152</identifier><identifier>PMID: 23472879</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Aged ; Brachial Artery ; Cohort Studies ; Drug Tolerance ; Female ; Forearm ; heart failure ; Heart Failure - drug therapy ; Heart Failure - metabolism ; Heart Failure - physiopathology ; Hemodynamics - drug effects ; Humans ; In Vitro Techniques ; Infusions, Intra-Arterial ; Male ; Metabolic Clearance Rate ; Middle Aged ; Nitric Oxide - administration &amp; dosage ; Nitric Oxide - analogs &amp; derivatives ; Nitric Oxide - metabolism ; Nitric Oxide - pharmacokinetics ; Nitroglycerin - administration &amp; dosage ; Nitroglycerin - metabolism ; Nitroglycerin - pharmacokinetics ; Nitroglycerin - pharmacology ; Oxidative Stress - drug effects ; Regional Blood Flow - drug effects ; Research Papers ; Saphenous Vein - drug effects ; Saphenous Vein - physiopathology ; sodium nitrite ; Sodium Nitrite - administration &amp; dosage ; Sodium Nitrite - metabolism ; Sodium Nitrite - pharmacokinetics ; Sodium Nitrite - pharmacology ; vascular effects ; Vasodilation - drug effects ; Vasodilator Agents - administration &amp; dosage ; Vasodilator Agents - metabolism ; Vasodilator Agents - pharmacokinetics ; Vasodilator Agents - pharmacology ; Vasomotor System - drug effects ; Vasomotor System - physiopathology</subject><ispartof>British journal of pharmacology, 2013-06, Vol.169 (3), p.659-670</ispartof><rights>2013 The Authors. British Journal of Pharmacology © 2013 The British Pharmacological Society</rights><rights>2013 The Authors. British Journal of Pharmacology © 2013 The British Pharmacological Society.</rights><rights>British Journal of Pharmacology © 2013 The British Pharmacological Society</rights><rights>British Journal of Pharmacology © 2013 The British Pharmacological Society 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4762-15ec056cc388b3837003ca71b5d15c4d8c5cbf01ed2cb294a03905170d5b403b3</citedby><cites>FETCH-LOGICAL-c4762-15ec056cc388b3837003ca71b5d15c4d8c5cbf01ed2cb294a03905170d5b403b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682712/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682712/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23472879$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maher, Abdul R</creatorcontrib><creatorcontrib>Arif, Sayqa</creatorcontrib><creatorcontrib>Madhani, Melanie</creatorcontrib><creatorcontrib>Abozguia, Khalid</creatorcontrib><creatorcontrib>Ahmed, Ibrar</creatorcontrib><creatorcontrib>Fernandez, Bernadette O</creatorcontrib><creatorcontrib>Feelisch, Martin</creatorcontrib><creatorcontrib>O'Sullivan, AG</creatorcontrib><creatorcontrib>Christopoulos, Arthur</creatorcontrib><creatorcontrib>Sverdlov, Aaron L</creatorcontrib><creatorcontrib>Ngo, Doan</creatorcontrib><creatorcontrib>Dautov, Rustem</creatorcontrib><creatorcontrib>James, Philip E</creatorcontrib><creatorcontrib>Horowitz, John D</creatorcontrib><creatorcontrib>Frenneaux, Michael P</creatorcontrib><title>Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>Background and Purpose Nitrite (NO2−) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO2− in healthy volunteers and patients with stable congestive heart failure (CHF). Experimental Approach The acute haemodynamic effects of brachial artery infusion of NO2− (0.31 to 7.8 μmol·min−1) was assessed in normal subjects (n = 20) and CHF patients (n = 21). Key Results NO2− infusion was well tolerated in all subjects. Forearm blood flow (FBF) increased markedly in CHF patients at NO2− infusion rates which induced no changes in normal subjects (anova: F = 5.5; P = 0.02). Unstressed venous volume (UVV) increased even with the lowest NO2− infusion rate in all subjects (indicating venodilation), with CHF patients being relatively hyporesponsive compared with normal subjects (anova: F = 6.2; P = 0.01). There were no differences in venous blood pH or oxygen concentration between groups or during NO2− infusion. Venous plasma NO2− concentrations were lower in CHF patients at baseline, and rose substantially less with NO2− infusion, without incremental oxidative generation of nitrate, consistent with accelerated clearance in these patients. Plasma protein‐bound NO concentrations were lower in CHF patients than normal subjects at baseline. This difference was attenuated during NO2− infusion. Prolonged NO2− exposure in vivo did not induce oxidative stress, nor did it induce tolerance in vitro. Conclusions and Implications The findings of arterial hyper‐responsiveness to infused NO2− in CHF patients, with evidence of accelerated transvascular NO2− clearance (presumably with concomitant NO release) suggests that NO2− effects may be accentuated in such patients. These findings provide a stimulus for the clinical exploration of NO2− as a therapeutic modality in CHF.</description><subject>Aged</subject><subject>Brachial Artery</subject><subject>Cohort Studies</subject><subject>Drug Tolerance</subject><subject>Female</subject><subject>Forearm</subject><subject>heart failure</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - metabolism</subject><subject>Heart Failure - physiopathology</subject><subject>Hemodynamics - drug effects</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Infusions, Intra-Arterial</subject><subject>Male</subject><subject>Metabolic Clearance Rate</subject><subject>Middle Aged</subject><subject>Nitric Oxide - administration &amp; dosage</subject><subject>Nitric Oxide - analogs &amp; derivatives</subject><subject>Nitric Oxide - metabolism</subject><subject>Nitric Oxide - pharmacokinetics</subject><subject>Nitroglycerin - administration &amp; dosage</subject><subject>Nitroglycerin - metabolism</subject><subject>Nitroglycerin - pharmacokinetics</subject><subject>Nitroglycerin - pharmacology</subject><subject>Oxidative Stress - drug effects</subject><subject>Regional Blood Flow - drug effects</subject><subject>Research Papers</subject><subject>Saphenous Vein - drug effects</subject><subject>Saphenous Vein - physiopathology</subject><subject>sodium nitrite</subject><subject>Sodium Nitrite - administration &amp; dosage</subject><subject>Sodium Nitrite - metabolism</subject><subject>Sodium Nitrite - pharmacokinetics</subject><subject>Sodium Nitrite - pharmacology</subject><subject>vascular effects</subject><subject>Vasodilation - drug effects</subject><subject>Vasodilator Agents - administration &amp; dosage</subject><subject>Vasodilator Agents - metabolism</subject><subject>Vasodilator Agents - pharmacokinetics</subject><subject>Vasodilator Agents - pharmacology</subject><subject>Vasomotor System - drug effects</subject><subject>Vasomotor System - physiopathology</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAUhS1ERYfCghdAltjAIq1_4rFngwQV_ZEqtQtYW87NzcQlsYOdDOrb4zKlokh448X99PlcH0LecHbMyzlppv6YC67EM7LitV5XShr-nKwYY7ri3JhD8jLnW8bKUKsX5FDIWgujNyuyvRwnBzONHYU-xeCBQgxbzLPfIe3RpZl2zg9LQhoDnXqXRgfxuw84e8jUhZbuXI5jnGOi2HUIc763-dAtGVsa_Jz8jK_IQeeGjK8f7iPy7ezL19OL6ur6_PL001UFJbeouEJgag0gjWmkkZoxCU7zRrVcQd0aUNB0jGMroBGb2jG5YYpr1qqmZrKRR-Tj3jstzYgtYJiTG-yU_OjSnY3O26eT4Hu7jTsr10ZoLorg_YMgxR9L-Qc7-gw4DC5gXLLlJVR5WEtW0Hf_oLdxSaGsZ0sXZi3qut4U6sOeghRzTtg9huHM3tdnS332d32Ffft3-kfyT18FONkDP_2Ad_832c83F3vlL8EqpbU</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Maher, Abdul R</creator><creator>Arif, Sayqa</creator><creator>Madhani, Melanie</creator><creator>Abozguia, Khalid</creator><creator>Ahmed, Ibrar</creator><creator>Fernandez, Bernadette O</creator><creator>Feelisch, Martin</creator><creator>O'Sullivan, AG</creator><creator>Christopoulos, Arthur</creator><creator>Sverdlov, Aaron L</creator><creator>Ngo, Doan</creator><creator>Dautov, Rustem</creator><creator>James, Philip E</creator><creator>Horowitz, John D</creator><creator>Frenneaux, Michael P</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7U7</scope><scope>C1K</scope><scope>5PM</scope></search><sort><creationdate>201306</creationdate><title>Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite</title><author>Maher, Abdul R ; Arif, Sayqa ; Madhani, Melanie ; Abozguia, Khalid ; Ahmed, Ibrar ; Fernandez, Bernadette O ; Feelisch, Martin ; O'Sullivan, AG ; Christopoulos, Arthur ; Sverdlov, Aaron L ; Ngo, Doan ; Dautov, Rustem ; James, Philip E ; Horowitz, John D ; Frenneaux, Michael P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4762-15ec056cc388b3837003ca71b5d15c4d8c5cbf01ed2cb294a03905170d5b403b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Brachial Artery</topic><topic>Cohort Studies</topic><topic>Drug Tolerance</topic><topic>Female</topic><topic>Forearm</topic><topic>heart failure</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - metabolism</topic><topic>Heart Failure - physiopathology</topic><topic>Hemodynamics - drug effects</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Infusions, Intra-Arterial</topic><topic>Male</topic><topic>Metabolic Clearance Rate</topic><topic>Middle Aged</topic><topic>Nitric Oxide - administration &amp; dosage</topic><topic>Nitric Oxide - analogs &amp; derivatives</topic><topic>Nitric Oxide - metabolism</topic><topic>Nitric Oxide - pharmacokinetics</topic><topic>Nitroglycerin - administration &amp; dosage</topic><topic>Nitroglycerin - metabolism</topic><topic>Nitroglycerin - pharmacokinetics</topic><topic>Nitroglycerin - pharmacology</topic><topic>Oxidative Stress - drug effects</topic><topic>Regional Blood Flow - drug effects</topic><topic>Research Papers</topic><topic>Saphenous Vein - drug effects</topic><topic>Saphenous Vein - physiopathology</topic><topic>sodium nitrite</topic><topic>Sodium Nitrite - administration &amp; dosage</topic><topic>Sodium Nitrite - metabolism</topic><topic>Sodium Nitrite - pharmacokinetics</topic><topic>Sodium Nitrite - pharmacology</topic><topic>vascular effects</topic><topic>Vasodilation - drug effects</topic><topic>Vasodilator Agents - administration &amp; dosage</topic><topic>Vasodilator Agents - metabolism</topic><topic>Vasodilator Agents - pharmacokinetics</topic><topic>Vasodilator Agents - pharmacology</topic><topic>Vasomotor System - drug effects</topic><topic>Vasomotor System - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maher, Abdul R</creatorcontrib><creatorcontrib>Arif, Sayqa</creatorcontrib><creatorcontrib>Madhani, Melanie</creatorcontrib><creatorcontrib>Abozguia, Khalid</creatorcontrib><creatorcontrib>Ahmed, Ibrar</creatorcontrib><creatorcontrib>Fernandez, Bernadette O</creatorcontrib><creatorcontrib>Feelisch, Martin</creatorcontrib><creatorcontrib>O'Sullivan, AG</creatorcontrib><creatorcontrib>Christopoulos, Arthur</creatorcontrib><creatorcontrib>Sverdlov, Aaron L</creatorcontrib><creatorcontrib>Ngo, Doan</creatorcontrib><creatorcontrib>Dautov, Rustem</creatorcontrib><creatorcontrib>James, Philip E</creatorcontrib><creatorcontrib>Horowitz, John D</creatorcontrib><creatorcontrib>Frenneaux, Michael P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maher, Abdul R</au><au>Arif, Sayqa</au><au>Madhani, Melanie</au><au>Abozguia, Khalid</au><au>Ahmed, Ibrar</au><au>Fernandez, Bernadette O</au><au>Feelisch, Martin</au><au>O'Sullivan, AG</au><au>Christopoulos, Arthur</au><au>Sverdlov, Aaron L</au><au>Ngo, Doan</au><au>Dautov, Rustem</au><au>James, Philip E</au><au>Horowitz, John D</au><au>Frenneaux, Michael P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2013-06</date><risdate>2013</risdate><volume>169</volume><issue>3</issue><spage>659</spage><epage>670</epage><pages>659-670</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><abstract>Background and Purpose Nitrite (NO2−) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO2− in healthy volunteers and patients with stable congestive heart failure (CHF). Experimental Approach The acute haemodynamic effects of brachial artery infusion of NO2− (0.31 to 7.8 μmol·min−1) was assessed in normal subjects (n = 20) and CHF patients (n = 21). Key Results NO2− infusion was well tolerated in all subjects. Forearm blood flow (FBF) increased markedly in CHF patients at NO2− infusion rates which induced no changes in normal subjects (anova: F = 5.5; P = 0.02). Unstressed venous volume (UVV) increased even with the lowest NO2− infusion rate in all subjects (indicating venodilation), with CHF patients being relatively hyporesponsive compared with normal subjects (anova: F = 6.2; P = 0.01). There were no differences in venous blood pH or oxygen concentration between groups or during NO2− infusion. Venous plasma NO2− concentrations were lower in CHF patients at baseline, and rose substantially less with NO2− infusion, without incremental oxidative generation of nitrate, consistent with accelerated clearance in these patients. Plasma protein‐bound NO concentrations were lower in CHF patients than normal subjects at baseline. This difference was attenuated during NO2− infusion. Prolonged NO2− exposure in vivo did not induce oxidative stress, nor did it induce tolerance in vitro. Conclusions and Implications The findings of arterial hyper‐responsiveness to infused NO2− in CHF patients, with evidence of accelerated transvascular NO2− clearance (presumably with concomitant NO release) suggests that NO2− effects may be accentuated in such patients. These findings provide a stimulus for the clinical exploration of NO2− as a therapeutic modality in CHF.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>23472879</pmid><doi>10.1111/bph.12152</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1188
ispartof British journal of pharmacology, 2013-06, Vol.169 (3), p.659-670
issn 0007-1188
1476-5381
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3682712
source MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central; Alma/SFX Local Collection
subjects Aged
Brachial Artery
Cohort Studies
Drug Tolerance
Female
Forearm
heart failure
Heart Failure - drug therapy
Heart Failure - metabolism
Heart Failure - physiopathology
Hemodynamics - drug effects
Humans
In Vitro Techniques
Infusions, Intra-Arterial
Male
Metabolic Clearance Rate
Middle Aged
Nitric Oxide - administration & dosage
Nitric Oxide - analogs & derivatives
Nitric Oxide - metabolism
Nitric Oxide - pharmacokinetics
Nitroglycerin - administration & dosage
Nitroglycerin - metabolism
Nitroglycerin - pharmacokinetics
Nitroglycerin - pharmacology
Oxidative Stress - drug effects
Regional Blood Flow - drug effects
Research Papers
Saphenous Vein - drug effects
Saphenous Vein - physiopathology
sodium nitrite
Sodium Nitrite - administration & dosage
Sodium Nitrite - metabolism
Sodium Nitrite - pharmacokinetics
Sodium Nitrite - pharmacology
vascular effects
Vasodilation - drug effects
Vasodilator Agents - administration & dosage
Vasodilator Agents - metabolism
Vasodilator Agents - pharmacokinetics
Vasodilator Agents - pharmacology
Vasomotor System - drug effects
Vasomotor System - physiopathology
title Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T19%3A57%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20chronic%20congestive%20heart%20failure%20on%20pharmacokinetics%20and%20vasomotor%20effects%20of%20infused%20nitrite&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Maher,%20Abdul%20R&rft.date=2013-06&rft.volume=169&rft.issue=3&rft.spage=659&rft.epage=670&rft.pages=659-670&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.12152&rft_dat=%3Cproquest_pubme%3E3316012971%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1528624449&rft_id=info:pmid/23472879&rfr_iscdi=true